The fragmented and document-based drug development process prevents R&D organizations to oversee the path to the targeted product and its benefits for patients.
Innovations usually focus on dis-integrated and isolated new technologies leading to further process fragmentation and neglect the disciplined design thinking, strategic planning, interaction and collaboration across the stake-holders.